HSA — authorised 25 October 2022
- Marketing authorisation holder: JANSSEN BIOTECH
- Status: likely_approved
🇸🇬 Bcmaxcd3 in Singapore
HSA authorised Bcmaxcd3 on 25 October 2022
Marketing authorisation
Bcmaxcd3 in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Oncology approved in Singapore
Frequently asked questions
Is Bcmaxcd3 approved in Singapore?
Yes. HSA authorised it on 25 October 2022.
Who is the marketing authorisation holder for Bcmaxcd3 in Singapore?
JANSSEN BIOTECH holds the Singaporean marketing authorisation.